查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1224626

光化性角化病治疗美国市场规模、份额和趋势分析:按治疗方法、药物类别、产品、用途、市场预测,2023-2030年

U.S. Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical/Drugs, Surgery, Photodynamic Therapy), By Drug Class, By Product, By End-use, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国光化性角化病治疗市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，美国光化性角化病治疗市场规模预计到 2030 年将达到 29.4 亿美元，预测期内以 3.03% 的复合年增长率扩大。 光化性角化病治疗服务的广泛应用和对光化性角化病 (AK) 治疗的认识不断提高预计将推动市场增长。 此外，对 AK 微创治疗的强劲需求和局部治疗方案的不断采用也有望支持市场增长。 例如，根据美国国立卫生研究院的数据，5%的5-氟尿嘧啶乳膏是光化性角化病的首选和最佳一线治疗药物。

消费者对 AK 等皮肤病的认识不断提高是该市场的主要增长动力。 增加对这种疾病的诊断和治疗策略的了解正在推动 AK 治疗的整体采用。 5-氟尿嘧啶、双氯芬酸和咪奎莫特等定点驱动的治疗药物有望在未来几年见证更大的市场渗透。 例如，临床试验表明，用含有咪奎莫特的製剂治疗的患者达到了大约 75% 的清除率。

此外，与局部光化性角化病製剂相关的高安全性和耐受性因素增加了对治疗光化性角化病的局部药物的需求。 例如，在 clinicaltrials.gov 上发布的局部 AK 的 3 期临床试验发现局部 AK 没有严重的副作用。 虽然一些製剂会引起局部皮肤刺激，如过敏，但更新的局部製剂，如替凡尼碱和 ingenol mebutate 显示出更好的耐受性，有望推动市场增长。

根据 NIH 的说法，与单一疗法相比，光动力疗法和局部药物的结合提高了清除率。 此外，根据发表在 Healio 杂誌上的一项研究，20% 氨基乙□丙酸和 PDT 的组合在 AK 中显示出良好的结果，几乎没有副作用。 因此，预计在预测期内，治疗光化性角化病的联合疗法将推动市场增长。

此外，主要进入者正在采取战略举措，例如产品发布、扩张和合作伙伴关係等战略，以增加他们的市场份额。 例如，2021 年 2 月，领先的生物製药公司 Athenex, Inc. 在美国推出了 Klisyri 用于治疗头皮光化性角化病。我们宣布将获得更多领域的许可。

美国光化性角化病治疗市场报告要点

由于完全治癒的高需求和冷冻疗法的渗透，外科领域的份额最大。

光动力疗法由于其高位点特异性和极少的副作用记录了最快的增长速度

由于 Fluoplex、Carac 和 Fdex 的强劲商业表现以及对治疗早期疾病的外用製剂的高需求，核甘代谢抑製剂部分在 2022 年占据了最大的市场

/p>

从产品来看，5-氟尿嘧啶细分市场预计将在 2022 年主导美国光化性角化病治疗市场，而替凡尼细分市场有望快速增长

到 2022 年，由于在医院进行的医生主导的手术增加，医院部分将成为最大的部分

主导市场的主要参与者是 Bausch Health Companies, Inc.、LEO Pharma A/S、Almirall, S.A. 和 Biofrontera AG。

内容

第 1 章调查方法及范围

  • 市场细分和范围
    • 细分范围
    • 区域范围
  • 调查方法
  • 资讯采购
    • 购买的数据库：
    • GVR 内部数据库
    • 次要资讯
    • 初步调查
    • 初步调查的内容
  • 资讯或数据分析
    • 数据分析模型
  • 市场制定和验证
  • 模型详细资讯
    • 商品流分析
      • 方法：产品流方法
  • 调查假设
  • 二级资讯列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场展望
  • 竞争考虑

第 3 章美国光化性角化病治疗市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场
  • 市场动态
    • 市场促进因素分析
      • 疾病流行率增加
      • 预防策略
      • 易于获得治疗
    • 市场抑制因素分析
      • 缺乏消费者意识
      • 一般渗透
  • 描绘渗透率和增长前景
  • 流感疫苗：市场分析工具
    • 行业分析 - 波特五力分析
    • PESTLE 分析
  • 监管框架
  • 价格分析

第 4 章美国光化性角化病治疗市场细分分析，按治疗方式，2018-2030 年（百万美元）

  • 定义和范围
  • 2022 年和 2030 年治疗市场份额分析
  • 部门仪表板
  • 美国光化性角化病治疗市场，按治疗方式，2018-2030 年
  • 2018-2030 年市场规模和预测、趋势分析
    • 外用/药物
    • 手术
      • 冷冻疗法
      • 其他
    • 光动力疗法

第 5 章美国光化性角化病治疗市场细分分析，按产品分类，2018-2030 年（百万美元）（数量、销售额）

  • 定义和范围
  • 2022 年和 2030 年产品市场份额分析
  • 部门仪表板
  • 美国光化性角化病治疗市场，副产品，2018-2030
  • 2018-2030 年市场规模和预测、趋势分析
    • 5-氟尿嘧啶
      • Carac
      • Fluoroplex
      • Actikerall
      • Tolak
      • 其他
    • Diclofenac
      • Solaraze
      • Voltaren
      • Pennsaid
      • 其他
    • Imiquimod
      • Aldara
      • Zyclara
      • 其他
    • Tirbanibulin
    • Capecitabine
      • Xeloda
      • 其他
    • Aminolevulinic acid
      • Ameluz
      • Levulan
    • Porfimer sodium
    • 其他
      • Gemzar
      • Clolar
      • Vidaza
      • Metvix
      • 其他

第 6 章美国光化性角化病治疗市场细分分析，按药物类别，2018-2030 年（百万美元）

  • 定义和范围
  • 2022 年和 2030 年药物类别市场份额分析
  • 部门仪表板
  • 2018-2030 年按药物类别划分的美国光化性角化病治疗市场
  • 2018-2030 年市场规模和预测、趋势分析
    • 核甘代谢抑制剂
    • 非甾体抗炎药
    • 免疫反应调节剂
    • 增光剂
    • 其他

第 7 章美国光化性角化病治疗市场细分分析，按最终用途，2018-2030（百万美元）

  • 定义和范围
  • 2022 年和 2030 年终端用途市场份额分析
  • 部门仪表板
  • 按最终用途划分的美国光化性角化病治疗市场 2018-2030
  • 2018-2030 年市场规模和预测、趋势分析
    • 医院
    • 私人诊所
    • 家庭护理
    • 其他

第 8 章美国光化性角化病治疗市场细分分析，按地区划分，2018-2030 年（百万美元）

  • 定义和范围
  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场概况
  • SWOT 分析
  • 2022-2030 年市场规模、预测、收入和趋势分析
    • 美国
      • 美国
      • 主要国家动态
      • 竞争场景
      • 监管框架
      • 赎回场景

第 9 章美国光化性角化病治疗市场-竞争分析

  • 主要市场进入者的近期趋势和影响分析
    • Ansov 矩阵
    • 热图分析
    • 对主要交易和战略联盟的分析
      • 合资企业
      • 许可协议
      • 产品发布
      • 会议和活动
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
  • 上市公司
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 私人公司
    • 主要初创公司名单
  • 公司简介
    • Bausch Health Companies, Inc.
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • LEO Pharma A/S
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Almirall, SA
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Biofrontera AG
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • GALDERMA
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Sun Pharmaceutical Industries Ltd
    • 公司概况
    • 财务业绩
    • 产品基准
    • 战略举措
  • Novartis AG
    • 公司概况
    • 财务业绩
    • 产品基准
    • 战略举措
  • Hill Dermaceuticals, Inc.
    • 公司概况
    • 财务业绩
    • 产品基准
    • 战略举措
  • Viatris Inc.
    • 公司概况
    • 财务业绩
    • 产品基准
    • 战略举措
  • 3M
    • 公司概况
    • 财务业绩
    • 产品基准
    • 战略举措
Product Code: GVR-4-68040-027-1

U.S. Actinic Keratosis Treatment Market Growth & Trends:

The U.S. actinic keratosis treatment market size is expected to reach USD 2.94 billion by 2030, expanding at a CAGR of 3.03% over the forecast period, according to a new report by Grand View Research, Inc. The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.

The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.

Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.

According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.

Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp.

U.S. Actinic Keratosis Treatment Market Report Highlights:

  • The surgery segment held the largest share owing to the higher demand for complete disease eradication and high penetration of cryotherapy procedures
  • The photodynamic therapy segment registered the fastest growth rate because of high site specificity and less incidence of side effects
  • The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease
  • Based on product, the 5-fluorouracil segment dominated the U.S. actinic keratosis treatment market in 2022, whereas, the tirbanibulin segment is anticipated to be the fastest-growing segment
  • The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals
  • Key players dominating the market include Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A.; and Biofrontera AG

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Competitive Insights

Chapter 3 U.S. Actinic Keratosis Treatment Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market
  • 3.2 Market Dynamics
    • 3.2.1 Market drivers analysis
      • 3.2.1.1 Increasing disease prevalence
      • 3.2.1.2 Preventive strategies
      • 3.2.1.3 Easy availability of treatment
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Lack of consumer awareness
      • 3.2.2.2 Generic penetration
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Influenza Vaccine: Market Analysis Tools
    • 3.4.1 Industry analysis - Porter's
    • 3.4.2 PESTLE analysis
  • 3.5 Regulatory Framework
  • 3.6 Pricing Analysis

Chapter 4 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Therapy Market Share Analysis, 2022 & 2030
  • 4.3 Segment Dashboard
  • 4.4 U.S. Actinic Keratosis Treatment Market, by Therapy, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 Topical/Drugs
      • 4.5.1.1 Topical/Drugs market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2 Surgery
      • 4.5.2.1 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.5.2.2 Cryotherapy
      • 4.5.2.2.1 Cryotherapy market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.5.2.3 Others
      • 4.5.2.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3 Photodynamic Therapy
      • 4.5.3.1 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Product 2018 - 2030 (USD Million) (Volume, Number of Units Sold)

  • 5.1 Definition and Scope
  • 5.2 Product Market Share Analysis, 2022 & 2030
  • 5.3 Segment Dashboard
  • 5.4 U.S. Actinic Keratosis Treatment Market, by Product, 2018 to 2030
  • 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.5.1 5-fluorouracil
      • 5.5.1.1 5-fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.2 Carac
      • 5.5.1.2.1 Carac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.3 Fluoroplex
      • 5.5.1.3.1 Fluoroplex market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.4 Actikerall
      • 5.5.1.4.1 Actikerall market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.5 Tolak
      • 5.5.1.5.1 Tolak market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.6 Others
      • 5.5.1.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.2 Diclofenac
      • 5.5.2.1 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.2 Solaraze
      • 5.5.2.2.1 Solaraze market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.3 Voltaren
      • 5.5.2.3.1 Voltaren market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.4 Pennsaid
      • 5.5.2.4.1 Pennsaid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.5 Others
      • 5.5.2.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.3 Imiquimod
      • 5.5.3.1 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.2 Aldara
      • 5.5.3.2.1 Aldara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.3 Zyclara
      • 5.5.3.3.1 Zyclara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.4 Others
      • 5.5.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.4 Tirbanibulin
      • 5.5.4.1 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.5 Capecitabine
      • 5.5.5.1 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.5.2 Xeloda
      • 5.5.5.2.1 Xeloda market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.5.3 Others
      • 5.5.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.6 Aminolevulinic acid
      • 5.5.6.1 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.6.2 Ameluz
      • 5.5.6.2.1 Ameluz market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.6.3 Levulan
      • 5.5.6.3.1 Levulan market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.7 Porfimer sodium
      • 5.5.7.1 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.8 Others
      • 5.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.2 Gemzar
      • 5.5.8.2.1 Gemzar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.3 Clolar
      • 5.5.8.3.1 Clolar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.4 Vidaza
      • 5.5.8.4.1 Vidaza market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.5 Metvix
      • 5.5.8.5.1 Metvix market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.6 Others
      • 5.5.8.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)

Chapter 6 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Drug Class Market Share Analysis, 2022 & 2030
  • 6.3 Segment Dashboard
  • 6.4 U.S. Actinic Keratosis Treatment Market, by Drug Class, 2018 to 2030
  • 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 6.5.1 Nucleoside metabolic inhibitors
      • 6.5.1.1 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2 Nonsteroidal anti-inflammatory drugs
      • 6.5.2.1 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3 Immune response modifiers
      • 6.5.3.1 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4 Photoenhancers
      • 6.5.4.1 Photoenhancers market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5 Others
      • 6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 U.S. Actinic Keratosis Treatment Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 End-use Market Share Analysis, 2022 & 2030
  • 7.3 Segment Dashboard
  • 7.4 U.S. Actinic Keratosis Treatment Market, by End-use, 2018 to 2030
  • 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 7.5.1 Hospitals
      • 7.5.1.1 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2 Private clinics
      • 7.5.2.1 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3 Homecare
      • 7.5.3.1 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.4 Others
      • 7.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2022 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 SWOT Analysis
  • 8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
    • 8.6.1 U.S.
      • 8.6.1.1 U.S. actinic keratosis treatment market estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.6.1.2 U.S.
      • 8.6.1.2.1 Key Country Dynamics
      • 8.6.1.2.2 Competitive Scenario
      • 8.6.1.2.3 Regulatory Framework
      • 8.6.1.2.4 Reimbursement Scenario

Chapter 9 U.S. Actinic Keratosis Treatment Market - Competitive Analysis

  • 9.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 9.1.1 Ansoff matrix
    • 9.1.2 Heat map analysis
    • 9.1.3 Major Deals and Strategic Alliances Analysis
      • 9.1.3.1 Joint Ventures
      • 9.1.3.2 Licensing Agreements
      • 9.1.3.3 Product Launches
      • 9.1.3.1 Conferences and Campaigns
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
  • 9.3 Vendor Landscape
    • 9.3.1 List of key distributors and channel partners
    • 9.3.2 Key customers
  • 9.4 Public Companies
    • 9.4.1 Competitive Dashboard Analysis
      • 9.4.1.1 Market Differentiators
  • 9.5 Private Companies
    • 9.5.1 List of key emerging companies
  • 9.6 Company Profiles
    • 9.6.1 Bausch Health Companies, Inc
      • 9.6.1.1 Company overview
      • 9.6.1.2 Financial performance
      • 9.6.1.3 Product benchmarking
      • 9.6.1.4 Strategic Initiatives
    • 9.6.2 LEO Pharma A/S
      • 9.6.2.1 Company overview
      • 9.6.2.2 Financial performance
      • 9.6.2.3 Product benchmarking
      • 9.6.2.4 Strategic Initiatives
    • 9.6.3 Almirall, S.A
      • 9.6.3.1 Company overview
      • 9.6.3.2 Financial performance
      • 9.6.3.3 Product benchmarking
      • 9.6.3.4 Strategic Initiatives
    • 9.6.4 Biofrontera AG
      • 9.6.4.1 Company overview
      • 9.6.4.2 Financial performance
      • 9.6.4.3 Product benchmarking
      • 9.6.4.4 Strategic Initiatives
    • 9.6.5 GALDERMA
      • 9.6.5.1 Company overview
      • 9.6.5.2 Financial performance
      • 9.6.5.3 Product benchmarking
      • 9.6.5.4 Strategic Initiatives
    • 9.6.6 Sun Pharmaceutical Industries Ltd
      • 9.6.6.1 Company overview
      • 9.6.6.2 Financial performance
      • 9.6.6.3 Product benchmarking
      • 9.6.6.4 Strategic Initiatives
    • 9.6.7 Novartis AG
      • 9.6.7.1 Company overview
      • 9.6.7.2 Financial performance
      • 9.6.7.3 Product benchmarking
      • 9.6.7.4 Strategic initiatives
    • 9.6.8 Hill Dermaceuticals, Inc
      • 9.6.8.1 Company overview
      • 9.6.8.2 Financial performance
      • 9.6.8.3 Product benchmarking
      • 9.6.8.4 Strategic initiatives
    • 9.6.9 Viatris Inc.
      • 9.6.9.1 Company overview
      • 9.6.9.2 Financial performance
      • 9.6.9.3 Product benchmarking
      • 9.6.9.4 Strategic initiatives
    • 9.6.10 3M
      • 9.6.10.1 Company overview
      • 9.6.10.2 Financial performance
      • 9.6.10.3 Product benchmarking
      • 9.6.10.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Leading market players anticipated to witness the highest growth
  • Table 4 U.S. actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 6 U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. actinic keratosis treatment market, by product, 2018 - 2030 (USD Million) (number of units sold)
  • Table 8 U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Product pipeline
  • Table 10 Regulatory framework
  • Table 11 Comparative study of brands available for diclofenac
  • Table 12 Comparative study of brands available for 5-Fluorouracil
  • Table 13 Comparative study of brands available for Imiquimod
  • Table 14 Treatments currently available for management of AK
  • Table 15 Comparative study of brands available for 5-Fluorouracil
  • Table 16 Comparative study of brands available for diclofenac
  • Table 17 Comparative study of brands available for Imiquimod
  • Table 18 Comparative study of brands available for Tirbanibulin
  • Table 19 Comparative study of brands available for Capecitabine
  • Table 20 Comparative study of brands available for Aminolevulinic acid
  • Table 21 Comparative study of brand available for Porfimer sodium
  • Table 22 Comparative study of brands available under others segment
  • Table 23 Key topical products for actinic keratosis, 2022
  • Table 24 Key surgical procedures for actinic keratosis, 2022
  • Table 25 Key photodynamic therapeutics for actinic keratosis, 2022
  • Table 26 Key nucleoside metabolic inhibitors for actinic keratosis
  • Table 27 Key NSAIDs for actinic keratosis
  • Table 28 Key immune response modifiers for actinic keratosis
  • Table 29 Key photo enhancers for actinic keratosis
  • Table 30 Other drug classes for actinic keratosis
  • Table 31 Key physician-managed treatment for actinic keratosis
  • Table 32 Key home-based treatment for actinic keratosis
  • Table 33 Leading market players anticipated to witness the highest growth
  • Table 34 Key companies undergoing expansions
  • Table 35 Key companies undertaking acquisitions
  • Table 36 Key companies undergoing collaborations
  • Table 37 Key companies launching new products/services
  • Table 38 Key companies undergoing other strategies

List of Figures

  • Fig. 1 U.S. actinic keratosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Consumer behavior analysis
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 U.S. actinic keratosis treatment market: Product outlook and key takeaways
  • Fig. 20 U.S. actinic keratosis treatment market: Product movement analysis
  • Fig. 21 Product segment dashboard
  • Fig. 22 5-Fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 23 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 24 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 25 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 26 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 27 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 28 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 30 U.S. actinic keratosis treatment market: Therapy outlook and key takeaways
  • Fig. 31 U.S. actinic keratosis treatment market: Therapy movement analysis
  • Fig. 32 Therapy segment dashboard
  • Fig. 33 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. actinic keratosis treatment market: Drug class outlook and key takeaways
  • Fig. 37 U.S. actinic keratosis treatment market: Drug class movement analysis
  • Fig. 38 Drug class segment dashboard
  • Fig. 39 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Photo enhancers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. actinic keratosis treatment market: End-use outlook and key takeaways
  • Fig. 45 U.S. actinic keratosis treatment market: End-use movement analysis
  • Fig. 46 End-use segment dashboard
  • Fig. 47 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 U.S. actinic keratosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Ansoff Matrix
  • Fig. 54 Heat map analysis
  • Fig. 55 Market differentiators
  • Fig. 56 Market participant categorization
  • Fig. 57 U.S. actinic keratosis treatment market share analysis, 2022
  • Fig. 58 Strategic framework